SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.320
-0.160 (-4.60%)
Jun 3, 2026, 12:23 PM EDT - Market open
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, SAB Biotherapeutics stock has a consensus rating of "Strong Buy" and an average price target of $10.1. The average 1-year stock price forecast is 204.22% higher than the current stock price, while the lowest is $6.00 (+80.72%) and the highest is $15 (+351.81%).
Price Target: $10.1 (+204.22%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SAB Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Initiates $11 | Buy | Initiates | $11 | +231.33% | May 22, 2026 |
| Jefferies | Jefferies | Buy Initiates $11 | Buy | Initiates | $11 | +231.33% | May 20, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $15 | Buy | Maintains | $15 | +351.81% | May 14, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $14 | Buy | Reiterates | $14 | +321.69% | May 13, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $10 | Buy | Reiterates | $10 | +201.20% | May 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
62.50K
EPS This Year
-1.03
from -0.79
EPS Next Year
-0.72
from -1.03
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.65 | ||
| Avg | -1.03 | ||
| Low | -1.56 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.